"A fundamental U.S. biotech patent expired last week (May 5), accompanied by a flurry of legal activity. The patent holder and its licensee filed a patent-infringement lawsuit the day before the patent's expiration. They also asked the US Patent and Trade Office (USPTO) to extend the life of the patent.
Massachusetts biotech firm Repligen and the Massachusetts Institute of Technology (MIT) filed suit May 4 in US District Court, Boston, in which they allege patent infringement by ImClone Systems Inc., in the development and manufacturing processes of its anti-cancer drug, Erbitux (Cetuximab)."
“Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.”BIOINFORMATICS IN THE 21st CENTURY
the panda's thumb
bioinformatics.org / nodalpoint / flags and lollipops / on genetics / a bioinformatics blog / andrew dalke / the struggling grad student / in the pipeline / gene expression / free association / pharyngula / the personal genome / genetics and public health blog / the medical informatics weblog / linuxmednews / nanodot / complexity digest /
nsu / nyt science / bbc scitech / newshub / biology news net /
informatics review / stanford / bmj info in practice / bmj info in practice /
look snazzy and support the site at the same time by buying some snowdeal schwag !
valid xhtml 1.0?
This site designed by
Eric C. Snowdeal III .